91% higher than its 30-day average trading volume of 25. Aytu is selling the test under emergency FDA guidance. Cruz Announces Investigation on Behalf of Aytu BioScience Inc. The Law Offices of Frank R. Financial summary and company information for Aytu BioScience Inc AYTU U. is a healthcare company which focused on commercialization of novel products in the field of urology. ’s (NASDAQ:AYTU): Aytu BioScience, Inc. Share Story. 32 from the previous closing price of $1. PR Newswire: 08. Mark Pimentel, who is leading the project: "Our team has shown that administering a specific spectrum of UV-A light can eradicate viruses in infected. The firm owned 31,289 shares of the company’s stock after purchasing an additional 8,699 shares during the quarter. Find Aytu BioScience earnings date, updates and upcoming Aytu BioScience earnings report Sep 1, 2020 as well as EPS Forecast and AYTU top analyst price target consensus for Aytu BioScience News Research Tools. Find the latest news headlines from Aytu BioScience, Inc. What about the future for Aytu Bioscience? The high forecast for Aytu Bioscience is 5. 46% move from the prior day. Shares of Aytu Bioscience Inc (NASDAQ:AYTU) gapped up prior to trading on Friday. march 17 (reuters) - aytu bioscience inc: * aytu bioscience inc - announces acceleration of u. Aytu BioScience had signed a deal with Cedars-Sinai to develop and. 99, and the consensus price target is $3. The MarketWatch News Department was not involved in the creation of this content. ENGLEWOOD, CO / ACCESSWIRE / July 30, 2020 / Aytu BioScience, Inc. 00 with a high forecast of $3. 13G Filing: Armistice Capital and Aytu Bioscience Inc (AYTU) Published on August 25, 2017 at 3:08 pm by Insider Monkey Staff in Hedge Funds Share Tweet Email. Monday, Apr 27, 2020. COVID-19 IgG/IgM Rapid Test. About Aytu BioScience, Inc. - AYTU Stock Chart Technical Analysis for 04-15-2020 - Duration: 3:34. (NASDAQ:AYTU) Aytu BioScience, Inc. Its products include Natesto, Tuzistram, ZolpiMist and. Aytu BioScience Announces Expansion Of NATESTO US Commercial Team Commercial Partner Acerus Pharmaceuticals Launches Specialty Sales Team Calling on Urologists and Endocrinologists in the United States ENGLEWOOD, CO / ACCESSWIRE / July 20, 2020 / Aytu BioScience, Inc. Other News for AYTU INO, DVAX among premarket gainers 06/26/20-7:27AM EST Seeking Alpha 20 Healthcare Stocks Moving In Friday`s Pre-Market Session 06/26/20-6:44AM EST Aytu BioScience News: This is the News-site for the company Aytu BioScience on Markets Insider Aytu BioScience, Inc. {"success":true,"data":{"counter":{"counter":"8YY. (AYTU) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). Stock analysis for Aytu BioScience Inc (AYTU:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Aytu Bioscience (NASDAQ:AYTU) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Tuesday, Zacks. This morning, before the markets opened, NBC News issued a report entitled “Unapproved Chinese coronavirus antibody tests being used in at. Historical Performance In The News: Taking a look at the performance of Aytu BioScience, Inc. News 7/31/2020. 18 is the 14-day ATR for Aytu BioScience Inc. (a) Given that the Company had entered into the distributorship agreement with Aytu today, 23 Apr 2020, please disclose if the Company had been aware of the development pertaining to Aytu. Find the latest news headlines from Aytu BioScience, Inc. Luoxis was merged into Aytu in April 2015 following Luoxis’ development of the technology behind the company’s MiOXSYS in vitro diagnostic platform. View the AYTU report for unscheduled material events or corporate changes by date. Mark Pimentel, who is leading the project: "Our team has shown that administering a specific spectrum of UV-A light can eradicate viruses in infected. 99 on volume of 21,555,025 shares. 86 Monday morning. 2 million Aytu shares. ENGLEWOOD, CO / ACCESSWIRE / July 30, 2020 / Aytu BioScience , Inc. 83% compared to the previous close of $1. The split for AYTU took place on August 13, 2018. Twitter later reversed its censorship, saying the company's account was "mistakenly" caught in a spam filter. Aytu Bioscience Inc (AYTU) stock is lower by 8. The company has a current ratio of 1. (AYTU) stock price, news, historical charts, analyst ratings and financial information from WSJ. 35 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Do the numbers hold clues to what lies ahead for the. 07-31 zacks. Aytu BioScience Featured in Local NBC News Segment (VIDEO): ''Nasal Spray for Low Testosterone Preserves Fertility'' ENGLEWOOD, CO / ACCESSWIRE / June 12, 2019 / Aytu BioScience, Inc. When you contact NATESTO At Home, a dedicated case manager can help you access a number of services, including:. 4% americanbankingnews. 40 per share. The company’s shares closed last Wednesday at $1. Now to discuss some of the. Luoxis was merged into Aytu in April 2015 following Luoxis’ development of the technology behind the company’s MiOXSYS in vitro diagnostic platform. Includes articles, videos and real-time news from StockTwits. Wainwright reiterated a Buy rating on Aytu BioScience, with a price target of $3. 47% of loss with the last five trading sessions. AYTU Stock Rockets On Diagnostic News. distribution rights to Biolidics’s COVID-19 IgG/IgM Rapid Test. Aytu BioScience, Inc. For example, the pharmaceutical firm Aytu BioScience announced on April 20, four days before the Trump remarks, that it has signed an exclusive licensing deal with Cedars-Sinai Medical Center in. The lowest estimate earnings-per-share for the quarter is -$0. Get the latest AYTU BIOSCIENCE DL -,0001 (AY21. Get the latest Aytu BioScience, Inc. (AYTU) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2020. Get the latest COVID-19 news in Colorado. , a specialty pharmaceutical company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), cough and upper respiratory symptoms, insomnia, and male infertility in the United States and internationally. Aytu BioScience had signed a deal with Cedars-Sinai to develop and. SHEEPWOLF'S $1,000,000. View real-time stock prices and stock quotes for a full financial overview. Net Loss for the year was (25. is a healthcare company which focused on commercialization of novel products in the field of urology. (AYTU) (the "Company"), a specialty pharmaceutical company. The high price target for AYTU is $5. It is meant solely to illustrate how Healight is designed to work. About Aytu BioScience, Inc. Aytu BioScience Inc. 32 from the previous closing price of $1. 51%, respectively, for the quarter ended March 2020. Find the latest Aytu BioScience, Inc. 01 M ) with profit before overhead, payroll, taxes, and interest of 5. 25GHz 4GB 16GB SSD 11. WKN A2NB17 | ISIN US0547547002 | Aytu Bioscience Aktie mit aktuellem Realtime Kurs, Chart, Nachrichten, Fundamentaldaten, Analysen, Meinungen & Empfehlungen. InvestorsObserver is giving Aytu Bioscience Inc (AYTU) an Analyst Rating Rank of 80, meaning AYTU is ranked higher by analysts than 80% of stocks. Get today's Aytu BioScience Inc stock price and latest AYTU news as well as Aytu BioScience real-time stock quotes, technical analysis, full financials and more. Now, the company has a potential treatment under development. This technology is still in research phase and not yet approved by the FDA for Emergency Use Application. 8K SEC filings breakout by MarketWatch. The company currently markets a portfolio. Analysts have been steadily raising their estimates for Aytu Bioscience, Inc. 47% of loss with the last five trading sessions. The 52-week range is $0. Monday, April 27, 2020. News Headlines for Aytu BioScience Inc. 15 per share versus the Zacks Consensus Estimate of a loss of $0. distribution agreement to distribute the Zhejiang Orient Gene rapid test on March 10, 2020. 98, a quick ratio of 1. (NASDAQ:AYTU), a specialty pharmaceutical company (the "Company") focused on commercializing novel products that address significant patient needs, today announced the approval of ZolpiMist® (zolpidem. (US:AYTU) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. stock, an investor will come to know that the weekly performance for this stock is valued at -12. 86 Monday morning. Aytu BioScience (AYTU) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well. AYTU Bioscience partnered with a Hong-Kong based manufacturer to produce a test kit that takes anywhere between two to ten minutes to provide results. announced Monday that the company may begin the distribution of the first 100,000 COVID-19 IgG/IgM Rapid Tests throughout the country this week. Why This News Is So Exciting. Aytu Bioscience (AYTU) reported a 3rd Quarter March 2020 loss of $0. Under the transaction, Aytu will retire all outstanding Innovus common stock for an aggregate of up to $8m in Aytu common stock shares. According to Zacks, “Aytu BioScience, Inc. The Company markets a portfolio of prescription products addressing primary care and pediatric markets. * With the above news, AYTU’s stock rose 44% on the NASDAQ on Monday, April 27. 32 a year ago. We're updating this blog with the latest information regarding COVID-19 in Colorado. (NYSE MKT: AMPE) today announced that it intends to distribute most of its 11,626,068 shares of Aytu BioScience stock directly to Ampio shareholders. * Aytu BioScience Inc (AYTU) - $62. Get the latest COVID-19 news in Colorado. (AYTU) closed at $1. March 12, 2020 (Investorideas. Aytu began its focus on common conditions that affect millions of patients yet remain underserved with the current treatment options. (AYTU) Reports Q3 Loss, Tops Revenue Estimates Aytu Bioscience, Inc. Get the latest Aytu BioScience, Inc. The market expects Aytu Bioscience, Inc. Aytu Bioscience, Inc. This distribution will constitute over 70% of the Aytu shares outstanding at this time. Do the numbers hold clues to what lies ahead for the stock?. 45 before closing at $1. 35 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). News Thinking about buying stock in Citius Pharmaceuticals, Aytu Bioscience, Applied DNA Sciences, Royal Caribbean Cruises, or American Airlines? PR Newswire 06/26 09:31 ET. Announced Date May 9, 2017 Acquisition Type Acquisition. Aytu BioScience Announces Distribution Partnership with Apollo Med Innovations to Expand Distribution of COVID-19 IgG/IgM Rapid Test in United StatesACCESSWIRE | 07/10/2020 Aytu Bio expands U. 25, predicting that the stock has a possible upside of 312. 03 and has now fallen 3 days in a row. Luoxis was merged into Aytu in April 2015 following Luoxis' development of the technology behind the company's MiOXSYS in vitro diagnostic platform. (AYTU) stock price, news, historical charts, analyst ratings and financial information from WSJ. Interactive. Aytu BioScience is quickly positioning itself as a strong COVID-19 play. ENGLEWOOD, CO / ACCESSWIRE / July 30, 2020 / Aytu BioScience , Inc. Additional information for healthcare professionals, institutions, and other interested parties may be found below. What about the future for Aytu Bioscience? The high forecast for Aytu Bioscience is 5. Other News for AYTU INO, DVAX among premarket gainers 06/26/20-7:27AM EST Seeking Alpha 20 Healthcare Stocks Moving In Friday`s Pre-Market Session 06/26/20-6:44AM EST Aytu BioScience News: This is the News-site for the company Aytu BioScience on Markets Insider Aytu BioScience, Inc. - AYTU Stock Chart Technical Analysis for 04-15-2020 - Duration: 3:34. Aytu BioScience (NASDAQ: AYTU) is a growing specialty pharmaceutical company focused on commercializing novel products that address significant patient needs. Aytu BioScience Crushes Recent Quarter, Shares Slide. AYTU Stock Rockets On Diagnostic News. 95% in the past year of trading. Aytu Bioscience, Inc. Do the numbers hold clues to what lies ahead for the stock? Mon, May 11, 9:30 AM, Zacks. The company traded shares of 2. 51%, respectively, for the quarter ended March 2020. AYTU Bioscience partnered with a Hong-Kong based manufacturer to produce a test kit that takes anywhere between two to ten minutes to provide results. is a commercial-stage specialty pharmaceutical company focused on commercializing novel products that address significant patient needs. Under the transaction, Aytu will retire all outstanding Innovus common stock for an aggregate of up to $8m in Aytu common stock shares. (NASDAQ:AYTU) went down by -1. e-books and. Friday, October 05, 2018. In after-hours action, shares added another 6. We would expect to have it early next week here in Denver,” Josh Disbrow, the CEO of AYTU BioScience, said. # opko # opk # pennystocks # news # covid19 https://cstu. 75 over the next 12 months and analyst’s classify the stock as a Strong Buy. Find the latest news headlines from Aytu BioScience, Inc. 40 in the last trading session, with the day’s gains setting it 0. Investing in securities products involves risk, including possible loss of principal. 00 with a high forecast of $3. 99 and move down -176. Aytu Bioscience, Inc. Aytu Bioscience (NASDAQ:AYTU)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research report issued on Thursday, AnalystRatings. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. (NASDAQ: AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced that it has entered into. A replay of the call will be available for fourteen days. Their average twelve-month price target is $4. AYTU bioscience UV light a potential COVID-19 Dis-Infectant April 25, 2020 April 25, 2020 Aytu BioScience Signs Exclusive Global License with Cedars-Sinai for Potential Coronavirus Treatment in the form of “healite” UV light injection technology. Company Expects to Pursue Commercial Use Under FDA's Emergency Use Authorization ENGLEWOOD, CO / ACCESSWIRE / March 10, 2020 / Aytu BioScience, Inc. , the same company partnering. 33% over the past week and gets a Bearish rating from InvestorsObserver's Sentiment Indicator. (NASDAQ:AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced that the company will present its operational results for the quarter en. Friday, October 05, 2018. Find out if AYTU is overpriced or undervalued. Monday, Apr 27, 2020. 47%, resulting in a performance for the month at -24. Read current news for AYTU. Tuesday, April 30, 2019. The acquisition will […]. The Ascent is The Motley Fool's new personal finance brand devoted to helping you live a richer life. 08 on the last trading session with an decrease of -1. Aytu Bioscience, Inc. Aytu BioScience Announces Results from a National Cancer Institute Evaluation of the Company's Licensed COVID-19 IgG/IgM Rapid Test. ENGLEWOOD, CO / ACCESSWIRE / June 1, 2020 / Aytu BioScience, Inc. How we're improving patients' lives. 25, predicting that the stock has a possible upside of 312. AYTU | Complete Aytu BioScience Inc. Aytu BioScience Inc. ’s (NASDAQ:AYTU): Aytu BioScience, Inc. Wt (AYTUW) stock price, news, historical charts, analyst ratings and financial information from WSJ. 51 while the outstanding shares total 35. Historical Performance In The News: Taking a look at the performance of Aytu BioScience, Inc. 35 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). 9900 on 03/10/20, with the lowest value was $0. 08M shares in volume on a normal day but saw 3092694 shares change hands in Tuesday trading. 13G Filing: Armistice Capital and Aytu Bioscience Inc (AYTU) Published on August 25, 2017 at 3:08 pm by Insider Monkey Staff in Hedge Funds Share Tweet Email. Aytu Bioscience, Inc. 67%, resulting in a performance for the month at -23. 82% from its latest closing price when compared to the 1-year high value of $2. ENGLEWOOD -- Aytu BioScience, Inc. (AYTU) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2020. You can read further details here. Aytu BioScience, Inc. The company now has a market cap of 146. (AYTU) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). is a specialty pharmaceutical company. 40 in the last trading session, with the day’s gains setting it 0. Monday, April 27, 2020. Separately. Do the numbers hold clues to what lies ahead for the stock? Mon, May 11, 9:30 AM, Zacks. About Aytu BioScience, Inc. 51%, respectively, for the quarter ended March 2020. to appoint Aytu as an exclusive distributor for… Continue reading Press Release April 23, 2020 April 23, 2020. (AYTU) stock news and headlines to help you in your trading and investing decisions. aytu bioscience inc (aytu): * aytu bioscience announces emergency use authorization of covid-19 igg/igm rapid test. 500,000 Rapid Tests Cleared for Shipment to Company's Warehouse ENGLEWOOD, CO / ACCESSWIRE / April 30, 2020 / Aytu BioScience, Inc. So Lenovo® has developed the rugged ThinkPad 11e Chromebooks to perform and last longer, even under the roughest handling. 's (NASDAQ:AYTU): Aytu BioScience, Inc. 47% of loss with the last five trading sessions. is a specialty pharmaceutical company, which focuses on identifying, acquiring, and commercializing novel products. (NASDAQ:AYTU) Aytu BioScience is a commercial-stage specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs. 24/7 Wall St. Aytu BioScience Inc. (AYTU) Partner News. Get Aytu BioScience Inc (AYTU:NASDAQ) real-time stock quotes, news and financial information from CNBC. Friday, October 05, 2018. Read current news for AYTU. 99 and move down -176. The company has a market capitalization of $133. 2 Wall Street analysts have issued ratings and price targets for Aytu Bioscience in the last 12 months. Aytu Bioscience Inc (AYTU) stock is lower by 8. Separately. ValuEngine raised shares of Aytu Bioscience […]. Post-Market 0. (AYTU) came out with a quarterly loss of $0. NEW YORK — Specialty pharmaceutical firm Aytu BioScience said on Tuesday that it has exclusively licensed the US distribution rights for a point-of-care SARS-Cov-2 immunoassay developed by China's Zhejiang Orient Gene Biotech. This was a 1 for 20 reverse split, meaning for each 20 shares of AYTU owned pre-split, the shareholder now owned 1 share. (AYTU) stock price, news, historical charts, analyst ratings and financial information from WSJ. Aytu BioScience, Inc. (a) Given that the Company had entered into the distributorship agreement with Aytu today, 23 Apr 2020, please disclose if the Company had been aware of the development pertaining to Aytu. (AYTU) will achieve an EPS of $0 for the current quarter, -$0. Aytu BioScience announced a U. Monday, April 27, 2020. *Proposed prototype device depicted. We are investigating its Board of Directors for potential securities laws violations and/or breaches of fiduciary duties in connection with the Purchase Agreement with Cerecor Inc for its pediatric and primary care product lines (the "Purchase Agreement"). The company has a current ratio of 1. - AYTU Stock Chart Technical Analysis for 04-24-2020 - Duration: 3:17. Separately, Zacks Investment Research upgraded shares of Aytu Bioscience from a “hold” rating to a “buy” rating and set a $1. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced it has received confirmation from the U. Aytu Bioscience Inc (NASDAQ:AYTU) was the recipient of a significant increase in short interest in March. 06 Million on the trading day while its three month average volume stands at 6. (AYTU - Free Report) closed the most recent trading day at $1. Tuesday, April 30, 2019. Aytu BioScience, Inc. (AYTU - Free Report). News for Aytu BioScience Aytu BioScience. Aytu BioScience is a specialty pharmaceutical company focused on delivering novel therapeutics to improve the health of patients. (NASDAQ:AYTU) Aytu BioScience is a commercial-stage specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs. 76%) Utragenyx Shares Soar Above 60% YTD on Pipeline Developments Zacks Equity Research - Zacks Investment Research - Thu Jun 11, 9:21AM CDT. Investors (AYTU) Business Wire - 4/21/2020 8:23:00 PM Current Report Filing (8-k) Edgar (US Regulatory) - 4/20/2020 8:06:05 AM. 54% from its latest closing price when compared to the 1-year high value of $2. For example, the pharmaceutical firm Aytu BioScience announced on April 20, four days before the Trump remarks, that it has signed an exclusive licensing deal with Cedars-Sinai Medical Center in. (NASDAQ: AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced that Natesto. According to Zacks, “Aytu BioScience, Inc. 99 and move down -176. Monday, Apr 27, 2020. During the day the stock fluctuated 11. Separately. Aytu BioScience Inc News. Aytu Bioscience, Inc. Aytu BioScience (AYTU) stock price, charts, trades & the US's most popular discussion forums. Aytu BioScience Announces Expansion Of NATESTO US Commercial Team Commercial Partner Acerus Pharmaceuticals Launches Specialty Sales Team Calling on Urologists and Endocrinologists in the United States ENGLEWOOD, CO / ACCESSWIRE / July 20, 2020 / Aytu BioScience, Inc. 12 per share for the fiscal year ending June 2020, which represents a year-over-year change of 96. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. An Experimental Ultraviolet Light Treatment for Covid-19 Takes Political Heat The Wall Street Journal Interactive Edition. Aytu recently acquired exclusive U. The acquisition will […]. (a) Given that the Company had entered into the distributorship agreement with Aytu today, 23 Apr 2020, please disclose if the Company had been aware of the development pertaining to Aytu. 33% over the past week and gets a Bearish rating from InvestorsObserver's Sentiment Indicator. Earnings Estimate Revisions for Aytu Bioscience, Inc. 39 per share on revenue of $7. stock, an investor will come to know that the weekly performance for this stock is valued at -12. This particular test returns results at point of care within 10 minutes. InvestorsObserver is giving Aytu Bioscience Inc (AYTU) an Analyst Rating Rank of 80, meaning AYTU is ranked higher by analysts than 80% of stocks. Based on 1 analyst offering 12 month price targets for Aytu BioScience in the last 3 months. Monday, April 27, 2020. 25, predicting that the stock has a possible upside of 312. (AYTU) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). 47% of loss with the last five trading sessions. to expand the distribution of its COVID-19 antibody testing kits in the. 33% over the past week and gets a Bearish rating from InvestorsObserver's Sentiment Indicator. ("Aytu" or the Company") (NASDAQ: AYTU) investors concerning the Company and its officers’ possible violations of federal securities laws. Stock Information A strong commitment to growth. com reports. Aytu BioScience is a commercial-stage specialty pharmaceutical company focused on commercializing novel products that address significant patient needs. 45 before closing at $1. Earnings Estimate Revisions for Aytu Bioscience, Inc. This company is expected to earn -$0. stock news by MarketWatch. The company currently markets a portfolio of prescription products addressing large primary care and pediatric markets. (NASDAQ:AYTU) went down by -1. 40 per share. The average projection by analysts for AYTU is $2. Disbrow’s first pharmaceutical start-up was Arbor Pharmaceuticals, a company focused initially on pediatrics. Aytu BioScience's Sublicensee SUDA Pharmaceuticals Secures TGA Approval, Enabling Near-Term Commercialization of ZolpiMist ENGLEWOOD, CO / ACCESSWIRE / July 30, 2020 / Aytu BioScience, Inc. This video is for informational purposes only. (NASDAQ:AYTU) Commercial Portfolio Acquisition Overview Conference Call October 14, 2019 4:30 PM ET. Aytu BioScience Inc. new stories. , a specialty pharmaceutical company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), cough and upper respiratory symptoms, insomnia, and male infertility in the United States and internationally. 13G Filing: Armistice Capital and Aytu Bioscience Inc (AYTU) Published on August 25, 2017 at 3:08 pm by Insider Monkey Staff in Hedge Funds Share Tweet Email. About Aytu BioScience, Inc. 82% from its latest closing price when compared to the 1-year high value of $2. Aytu BioScience (NASDAQ: AYTU ) has signed a distribution agreement with Apollo Med Innovations to distribute the COVID-19 IgG/IgM Rapid Test Cassette to Apollo's network of over 1,000 practices across the U. (NASDAQ:AYTU) shares fell to a low of $1. (AYTU) delivered earnings and revenue surprises of 61. Financial summary and company information for Aytu BioScience Inc AYTU U. Aytu BioScience, Inc. Historical Performance In The News: Taking a look at the performance of Aytu BioScience, Inc. Company profile page for Aytu BioScience Inc including stock price, company news, press releases, executives, board members, and contact information. As we have seen, testing is the only effective way to contain the coronavirus. 06 Million on the trading day while its three month average volume stands at 6. 14 that acquired a majority stake in Hyperoptic Ltd. AYTU Bioscience partnered with a Hong-Kong based manufacturer to produce a test kit that takes anywhere between two to ten minutes to provide results. Its products include Natesto, Tuzistram, ZolpiMist and. Aytu BioScience Inc is a specialty pharmaceutical company commercializing novel products addressing patient needs. 35 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). COVID-19 IgG/IgM Rapid Test. Let’s not forget, the company recently licensed a coronavirus rapid test that is now being pushed into commercialization. Earnings Estimate Revisions for Aytu Bioscience, Inc. Aytu BioScience to manufacture Healight devices for use in COVID-19 studies. The firm acquired 37,690 shares of the company’s stock. The split for AYTU took place on August 13, 2018. Aytu Bioscience, Inc. This was a very big move. Aytu BioScience Inc. Aytu BioScience Financials: This is the Financials-site for the company Aytu BioScience on Markets Insider. SA Breaking News 07/10 08:14 ET Aytu BioScience Announces Distribution Partnership with Apollo Med Innovations to Expand Distribution of COVID-19 IgG/IgM Rapid Test in United States Accesswire 07/10 08:00 ET. 99, and the consensus price target is $3. 82% from its latest closing price when compared to the 1-year high value of $2. 19% so far this year. com - August 31 at 7:38 PM: Aytu Bioscience Inc (NASDAQ:AYTU) Sees Large Drop in Short Interest americanbankingnews. The company now has a market cap of 146. Collection of curated. The first paragraph: "The Law Offices of Frank R. On April 23, Aytu announced a licensing agreement with Singapore-based Biolidics for the exclusive U. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how. Aytu Bioscience Inc. , the same company partnering. Last week, Aytu BioScience announced that it licensed United States rights to commercialize a rapid COVID-19 diagnostic test from a Chinese company. 00 JOURNEY: $AYTU News Article - Aytu BioScience Announces Manufacture and Delivery of Healight(TM) Devices for - #5863762. 74 million, which was 69. The lowest estimate earnings-per-share for the quarter is -$0. 15) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0. Aytu Bioscience serves customers worldwide. 61%, whereas, it previously closed at $1. 99% in the past year of trading. The company markets Natesto. 47%, resulting in a performance for the month at -24. is a healthcare company which focused on commercialization of novel products in the field of urology. *Proposed prototype device depicted. View the latest Aytu BioScience Inc. Aytu BioScience (NASDAQ: AYTU) is a growing specialty pharmaceutical company focused on commercializing novel products that address significant patient needs. (AYTU) delivered earnings and revenue surprises of 61. * aytu bioscience - has received its first coronavirus disease 2019 igg/igm rapid test shipment containing 100,000 tests from manufacturer on march 31. Additional information for healthcare professionals, institutions, and other interested parties may be found below. (NASDAQ:AYTU) does about 7. stock, an investor will come to know that the weekly performance for this stock is valued at -11. Financial summary and company information for Aytu BioScience Inc AYTU U. Hyperoptic is a UK. Aytu Bioscience, Inc. For example, the pharmaceutical firm Aytu BioScience announced on April 20, four days before the Trump remarks, that it has signed an exclusive licensing deal with Cedars-Sinai Medical Center in. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how. ENGLEWOOD, CO / ACCESSWIRE / July 30, 2020 / Aytu BioScience, Inc. (AYTU) Quote Overview » News » Aytu Bioscience, Inc. (NASDAQ: AYTU) is focused on commercializing products related to upper respiratory problems, and its shares surged in March of 2020 when the company became a coronavirus stock. An Experimental Ultraviolet Light Treatment for Covid-19 Takes Political Heat The Wall Street Journal Interactive Edition. Aytu BioScience is a specialty pharmaceutical company focused on commercializing novel products in the field of urology. Aytu BioScience is a one-trick play around COVID-19 test distribution. (NASDAQ:AYTU) went down by -1. Now to discuss some of the. [AYTU] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -2. distribution of COVID-19 blood test with Apollo deal Seeking Alpha | 07/10/2020. In fact, Aytu BioScience stock is up 52% year to date and up over 100% in the past six months alone. 85%, while AYTU stocks collected -8. Josh Disbrow, CEO, AYTU, calls refers to the test as "a game-changer". 12 is the 14-day ATR for Aytu BioScience Inc. Aytu BioScience (NASDAQ: AYTU ) fiscal Q3 results : More news on: Aytu BioScience, Inc. 25, 2020 at 12:00 p. Aytu BioScience, Inc. The stock had previously closed at $1. Current stock quote for Aytu BioScience Inc. Currently at 0. Aytu BioScience is a commercial-stage specialty pharmaceutical company focused on commercializing novel products that address significant patient needs. , a specialty pharmaceutical company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), cough and upper respiratory symptoms, insomnia, and male infertility in the United States and internationally. Tag: Aytu Bioscience (AYTU) Red-Hot Coronavirus WatchList of Companies Poised for Profits Both the markets and investors have been badly scorched by the rapid spread of the coronavirus. Aytu BioScience is a commercial-stage specialty pharmaceutical company focused on commercializing novel products that address significant patient needs. The company has a current ratio of 1. 0% on a year-over-year basis. Aytu BioScience Inc (AYTU): * Aytu BioScience Inc (AYTU) - REPORTS REVENUE FOR THREE MONTHS ENDED MARCH 31, 2020 OF $8. ( AYTU ) including financial statements, level 2 data, and the latest Biotechnology news, research, and investment community discussion. 00 while the low is 3. The company markets a portfolio of prescription products addressing large therapeutic markets. The firm owned 31,289 shares of the company’s stock after purchasing an additional 8,699 shares during the quarter. Aytu BioScience, Inc. Aytu Bioscience Inc (NASDAQ:AYTU) was the recipient of a significant increase in short interest in March. Currently at 0. Aytu Bioscience (NASDAQ:AYTU) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Tuesday, Zacks. But it awaits approval from the Food and Drug Administration (FDA) for public use. 12:45 PM ET. Traders and investors may also choose to study the ATR or Average True Range when concentrating on technical inventory assessment. (AYTU) stock news and headlines to help you in your trading and investing decisions. Get today's Aytu BioScience Inc stock price and latest AYTU news as well as Aytu BioScience real-time stock quotes, technical analysis, full financials and more. 01 for the next quarter and $0. Monday, Apr 27, 2020. Aytu Bioscience serves customers worldwide. 61%, whereas, it previously closed at $1. ENGLEWOOD -- Aytu BioScience, Inc. - AYTU Stock Chart Technical Analysis for 04-15-2020 - Duration: 3:34. Get the latest Aytu BioScience, Inc. 25, predicting that the stock has a possible upside of 312. On April 23, Aytu announced a licensing agreement with Singapore-based Biolidics for the exclusive U. Aytu Biosciences also secured another exclusive deal for another rapid serological test with above 90% accuracy. Recently in News on July 30, 2020, Aytu BioScience Announces Regulatory Approval of ZolpiMist(R) by Australian Therapeutic Goods Administration. Real-time trade and investing ideas on Capricor Therapeutics Inc CAPR from the largest community of traders and investors. 73% in over the last four-week period, additionally plugging by 106. SINGAPORE: Biolidics Limited entered into a distribution agreement with Aytu Bioscience, Inc. 07-31 zacks. The average price target is $3. The 1-year high price for the company’s stock is recorded $2. In last 7 days, analysts came adjusting their opinions about stock’s EPS with nil upward and no downward revisions, an indication which could give clearer idea about the company’s short term price movement. AYTU Bioscience partnered with a Hong-Kong based manufacturer to produce a test kit that takes anywhere between two to ten minutes to provide results. (AYTU) shares reached a high of $1. Aytu BioScience, Inc. The primary care portfolio includes Natesto, the nasal formu lation of testosterone for men with hypogonadism, ZolpiMist, the oral spray prescription sleep aid, and Tuzistra XR, the. Shares of Aytu Bioscience Inc (NASDAQ:AYTU) gapped up prior to trading on Friday. 85%, while AYTU stocks collected -8. Analysts have been steadily raising their estimates for Aytu Bioscience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced that Natesto. Aytu Bioscience is based out of Englewood. Aytu Bioscience, Inc. A number of analysts have recently commented on the stock. , a specialty pharmaceutical company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), cough and upper respiratory symptoms, insomnia, and male infertility in the United States and internationally. Earnings Estimate Revisions for Aytu Bioscience, Inc. to appoint Aytu as an exclusive distributor for the Company’s rapid test kits for the Novel Coronavirus 2019 (“COVID-19 Rapid Test Kits”), in the United States of America (“USA”) for a duration of one year with an option for an additional one-year term. (AYTU) Outpaces Stock Market Gains: What You Should Know. 3352 for the same time period, recorded on 03/09/20. The acquisition will […]. News Research Tools. Yes Bank FPO Review | Should I Invest Aytu BioScience, Inc. Start a 14-day free trial to Morningstar Premium to unlock our price to fair value estimate. 18, 2017 /PRNewswire/ -- Aytu BioScience, Inc. Josh Disbrow, CEO, AYTU, calls refers to the test as "a game-changer". Aytu BioSciences (AYTU) Announces License Agreement For COVID-19 Test On March 10, 2020, Aytu BioSciences, a Colorado-based publicly-traded specialty pharmaceutical company, announced that it had reached a license agreement for the exclusive distribution of a Chinese-made test for COVID-19 antibodies in the U. (AYTU) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). Aytu Bioscience, Inc. (AYTU) CEO Josh Disbrow on Commercial Portfolio Acquisition Overview Conference (Transcript) | Seeking Alpha. (AYTU) delivered earnings and revenue surprises of 61. The 1-year high price for the company’s stock is recorded $2. This company is expected to earn -$0. There is no available coverage of Aytu BioScience, Inc. latest news. On March 10, 2020, Aytu reported that it reached a license agreement for the exclusive distribution of a point-of-care rapid test for certain COVID-19 antibodies in the U. Find the latest Aytu BioScience, Inc. ’s holdings in Aytu Bioscience were […] NASDAQ AYTU opened at $1. 00 while the low is 3. Aytu Bioscience Inc. 51%, respectively, for the quarter ended March 2020. 00 while the low is 2. , a specialty pharmaceutical company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), cough and upper respiratory symptoms, insomnia, and male infertility in the United States and internationally. is a commercial-stage specialty pharmaceutical company focused on commercializing novel products that address significant patient needs. March 12, 2020 (Investorideas. Investors might want to bet on Aytu Bioscience, Inc. 8K SEC filings breakout by MarketWatch. 04 for 2021. Historical Performance In The News: Taking a look at the performance of Aytu BioScience, Inc. Aytu is initially concentrating on hypogonadism (low testosterone), prostate cancer, urinary tract infections, and male infertility and plans to expand into other urological. new stories. The company has a market capitalization of $133. to appoint Aytu as an exclusive distributor for… Continue reading Press Release April 23, 2020 April 23, 2020. * aytu bioscience - has received its first coronavirus disease 2019 igg/igm rapid test shipment containing 100,000 tests from manufacturer on march 31. (AYTU) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). view AYTU stock price historical chart, Aytu BioScience stock data graph & market activity. Aytu BioScience Crushes Recent Quarter, Shares Slide. News for Aytu BioScience Inc. 0 million shares of common stock. Aytu BioScience Aytu BioScience is a specialty healthcare company focused on developing treatments for urological and related conditions. It is a matter of debate whether stock price prediction based on information in financial news can generate a strong buy or sell signal. This particular test returns results at point of care within 10 minutes. (AYTU) Reports Q3 Loss, Tops Revenue Estimates Aytu Bioscience, Inc. march 17 (reuters) - aytu bioscience inc: * aytu bioscience inc - announces acceleration of u. This compares to loss of $0. Aytu Bioscience Inc. Aytu Bioscience Inc (AYTU) stock is lower by 8. (AYTU) (the "Company"), a specialty pharmaceutical company. Aytu is initially concentrating on hypogonadism (low testosterone), prostate cancer, urinary tract infections, and male infertility and plans to expand into other urological. ENGLEWOOD, CO / ACCESSWIRE / July 30, 2020 / Aytu BioScience, Inc. Prior to co-founding Aytu BioScience, Josh was the Chief Operating Officer of Ampio Pharmaceuticals (NYSE MKT: AMPE) and co-founded and led the Luoxis Diagnostics subsidiary. 69% and a negative net margin of 172. We cover the latest Aytu BioScience headlines and breaking news impacting Aytu BioScience stock performance. 29% over the past week and gets a Neutral rating from InvestorsObserver's Sentiment Indicator. Wainwright reiterated a Buy rating on Aytu BioScience, with a price target of $3. The firm owned 31,289 shares of the company’s stock after purchasing an additional 8,699 shares during the quarter. Aytu Bioscience Inc (AYTU) stock has gained 2. Aytu BioScience Inc. Aytu Bioscience, Inc. This company is expected to earn -$0. Aytu BioScience shares are trading higher after the company announced the launch of its nationwide mobile coronavirus testing initiative. 9900 on 03/10/20, with the lowest value was $0. Under the terms of the Agreement, Aytu will exclusively distribute Biolidics’ COVID-19 IgG/IgM rapid antibody test in the United States. It is not instructive. $3 Aytu BioScience, Inc. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. In fact, Aytu BioScience stock is up 52% year to date and up over 100% in the past six months alone. Stock forecasts are based on human experience: Human traders based on their experience in terms of stock price patterns, volume changes, and market news/rumors regarding a particular stock. 40 in the last trading session, with the day’s gains setting it 0. SI","symbol":"8YY","market":"SI"},"stock_price":{"stock_name":"Biolidics","full_name":"BIOLIDICS LIMITED","last_done. 51%, respectively, for the quarter ended March 2020. On Aytu BioScience's (AYTU) upcoming earnings call, investor focus will be on its distribution right to commercialize the COVID-19 IgG/IgM Rapid Test in North America. The acquisition will […]. Separately. Aytu BioScience, Inc. 05:50 PM ET. The COVID-19 IgG/IgM (Whole Blood/Serum/Plasma) Rapid Test is a lateral flow immunoassay intended for the qualitative detection and differentiation of IgM and IgG antibodies to SARS-CoV-2 in human venous whole blood, plasma from anticoagulated blood (Li+ heparin, K2EDTA and sodium citrate), or serum. On April 23, Aytu announced a licensing agreement with Singapore-based Biolidics for the exclusive U. Gunnison County officials have reached out to United Biomedical Inc. Aytu Bioscience Inc (AYTU) stock is lower by 8. Earnings Estimate Revisions for Aytu Bioscience, Inc. Aytu BioScience Announces Expansion Of NATESTO US Commercial Team Commercial Partner Acerus Pharmaceuticals Launches Specialty Sales Team Calling on Urologists and Endocrinologists in the United States ENGLEWOOD, CO / ACCESSWIRE / July 20, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced that the company will present its operational results for the quarter en. 49 and dropped to a low of $1. 99 in the current 52-week trading range. This company is expected to earn -$0. News for Aytu BioScience Inc. 32 a year ago. This compares to loss of $0. Aytu BioScience, Inc. Loading Unsubscribe from Jorge Saenz? Aytu BioScience, Inc. Newlight Partners LP and Mubadala Investment Co were the sellers. News Thinking about buying stock in Citius Pharmaceuticals, Aytu Bioscience, Applied DNA Sciences, Royal Caribbean Cruises, or American Airlines? PR Newswire 06/26 09:31 ET. Find the latest news headlines from Aytu BioScience, Inc. 03 and has now fallen 3 days in a row. is a commercial-stage specialty pharmaceutical company focused on commercializing novel products that address significant patient needs. 4% from the July 15th total of 9,020,000 shares. 3352 for the same time period, recorded on 03/09/20. Better health means better living. 49 and dropped to a low of $1. The company's board replied in a filing on Sunday night that it does not expect a material impact on its business plans from its agreement with Nasdaq-listed Aytu BioScience. 24/7 Wall St. (AYTU) delivered earnings and revenue surprises of 61. (NASDAQ:AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced that the company will present its operational results for the quarter en. Aytu BioScience Inc. The company's marketed products consists of ProstaScint(R), Primsol(R) and MiOXSYS(TM) which addresses prostate cancer, urinary tract infections, male infertility and male sexual dysfunction. Common Stock (AYTU) at Nasdaq. AYTU’s previous close was $1. 07-31 zacks. distribution agreement to distribute the Zhejiang Orient Gene rapid test on March 10, 2020. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing. 95% in the past year of trading. Aytu BioScience Announces Manufacture and Delivery of Healight(TM) Devices for Use in COVID-19 Clinical Study Aug 5 LD Micro Announces Preliminary List of Presenters for the LD-500. Currently at 0. Aytu BioScience Announces Expansion of NATESTO (R) U. Post-Market 0. 85%, while AYTU stocks collected -8. Aytu BioScience, Inc. view AYTU stock price historical chart, Aytu BioScience stock data graph & market activity. to expand the distribution of its COVID-19 antibody testing kits in the. The news sent MRNA stock soaring. 00 while the low is $2. Currently at 0. The stock outpaced the S&P 500's daily gain of 0. 42% in over the last four-week period, additionally plugging by 92. is a specialty pharmaceutical company. News Corp is a network of leading companies in the worlds of diversified media, news, education, and information services. The company reported the previous year's revenue of 14. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Aytu BioScience Announces Results from a National Cancer Institute Evaluation of the Company’s Licensed COVID-19 IgG/IgM Rapid Test. Posted On: August 6, 2020. 18: Aytu BioScience Provides Fiscal Second Quarter 2018 Business Update - Live Conference Call and Webcast Today at 4:30 pm ET: PR Newswire: 01. Dow Jones, a News Corp company. Aytu BioScience, Inc. When you contact NATESTO At Home, a dedicated case manager can help you access a number of services, including:. Get the latest Aytu BioScience, Inc. Investors might want to bet on Aytu Bioscience, Inc. We would expect to have it early next week here in Denver,” Josh Disbrow, the CEO of AYTU BioScience, said. AYTU has fallen -$0. Historical Performance In The News: Taking a look at the performance of Aytu BioScience, Inc. Aytu BioScience Inc. is a specialty pharmaceutical company, which focuses on identifying, acquiring, and commercializing novel products. Their average twelve-month price target is $4. 08% while the S&P 500 has risen 3. The company has a market capitalization of $138. News Thinking about buying stock in Citius Pharmaceuticals, Aytu Bioscience, Applied DNA Sciences, Royal Caribbean Cruises, or American Airlines? PR Newswire 06/26 09:31 ET. Historical Performance In The News: Taking a look at the performance of Aytu BioScience, Inc. Aytu BioScience Announces Receipt of Initial Shipment of 100,000 COVID-19. Aytu BioScience Inc. The Aytu BioScience's statement quoted Dr. Find the latest historical data for Aytu BioScience, Inc. price-eps-surprise | Aytu Bioscience, Inc. Investors might want to bet on Aytu Bioscience, Inc. Do the numbers hold clues to what lies ahead for the stock?. 33% over the past week and gets a Bearish rating from InvestorsObserver's Sentiment Indicator. Company profile page for Aytu BioScience Inc including stock price, company news, press releases, executives, board members, and contact information. Get the latest Aytu BioScience, Inc. Aytu Bioscience (NASDAQ:AYTU) Frequently Asked Questions How has Aytu Bioscience's stock been impacted by Coronavirus? Aytu Bioscience's stock was trading at $1. Aytu BioScience Crushes Recent Quarter, Shares Slide. 95% in the past year of trading. Aytu BioScience, Inc. On the front line of testing is XSPA stock.